logo
  

CTI BioPharma: FDA Extends Review Period For Pacritinib For Treatment Of Myelofibrosis; Stock Down

CTI BioPharma Corp. (CTIC) said that the U.S. Food and Drug Administration has extended the review period for the New Drug Application or NDA for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis or MF with a baseline platelet count of <50 × 109/L.

The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022.

CTIC closed Tuesday regular trading at $2.25 down $0.41 or 15.41%. In the after-hours, the stock further dropped $0.42 or 18.67%.

The FDA had granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30, 2021.

In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24, 2021.

Earlier today, the FDA informed the company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
Follow RTT